News

May 5, 2022

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

May 4, 2022

Rhythm Pharmaceuticals to Present at BofA Securities 2022 Healthcare Conference

May 3, 2022

Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update

May 2, 2022

Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting

April 26, 2022

Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

April 8, 2022

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

April 6, 2022

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity

March 1, 2022

Rhythm Pharmaceuticals to Present at Cowen & Co. 42nd Annual Health Care Conference

March 1, 2022

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

February 24, 2022

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

February 23, 2022

Rhythm Pharmaceuticals Announces Promotions within its Executive Leadership Team

February 22, 2022

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 1, 2022

February 16, 2022

Rhythm Pharmaceuticals Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)

February 8, 2022

Rhythm Pharmaceuticals to Host Virtual Bardet-Biedl Syndrome (BBS) Event on February 16

January 13, 2022

Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity